DelveInsight’s, “Chronic Lymphocytic Leukemia Pipeline Insight 2025” report provides comprehensive insights about 55+ companies and 60+ pipeline drugs in Chronic Lymphocytic Leukemia (CLL) pipeline ...

Personalized drug treatments have outperformed chemotherapy for leukemia patients in a trial led by Leeds researchers. Newly ...

The VERONA trial evaluated the safety and efficacy of venetoclax with azacitidine in treatment-naïve adults with higher-risk MDS.

Pharma majors AbbVie and Roche were both trading lower early Tuesday after top-line results were announced from the global ...

AbbVie's Phase 3 VERONA trial in HR-MDS showed no overall survival benefit for venetoclax-azacitidine; existing uses of ...

Venclexta fails to meet survival goals in ABBV's phase III MDS study, marking another clinical setback for the cancer drug.

Aptose Biosciences has been thrown a financial lifeline by its own CEO while the leukemia-focused biotech scrambles around ...

AbbVie (ABBV) announced the global Phase 3 Vevrona trial evaluating venetoclax in combination with azacitidine in the treatment of newly diagnosed higher-risk myelodysplastic syndrome did not meet the ...

AbbVie is deploying more capital into its pipeline, which features 50 programs in mid- and late-stage development and over ...

The findings of the UK-wide study, led by researchers from Leeds, could reshape the way the most common form of leukaemia in ...

SOUTH SAN FRANCISCO, CA, USA I June 16, 2025 I Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), and AbbVie announced today the outcome ...

FREMONT, CA, UNITED STATES, June 16, 2025 /EINPresswire.com/ -- NEXCOM, a leading global supplier of embedded systems, announced today the launch of the EBC 370/EBC 370X, providing Edge AI computing ...